Key statistics
On Thursday, Crinetics Pharmaceuticals Inc (6Z4:MUN) closed at 47.80, -4.02% below its 52-week high of 49.80, set on Jul 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 47.80 |
---|---|
High | 47.80 |
Low | 47.80 |
Bid | 48.20 |
Offer | 48.40 |
Previous close | 47.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 80.04m |
Free float | 76.89m |
P/E (TTM) | -- |
Market cap | 4.22bn USD |
EPS (TTM) | -3.77 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 07:06 BST.
More ▼
Announcements
- Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
- Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
- Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
- Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
- EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
- Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
- Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
More ▼